List of Tables
Table 1. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Trends
Table 2. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Drivers & Opportunity
Table 3. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Challenges
Table 4. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Restraints
Table 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Type
Table 9. Key Companies Time to Begin Mass Production of Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics
Table 10. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Region (2019-2024) & (%)
Table 27. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, (2025-2030) & (US$ Million)
Table 31. Allergan plc Basic Information List
Table 32. Allergan plc Description and Business Overview
Table 33. Allergan plc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 34. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Allergan plc (2019-2024)
Table 35. Allergan plc Recent Developments
Table 36. Pfizer Inc Basic Information List
Table 37. Pfizer Inc Description and Business Overview
Table 38. Pfizer Inc Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 39. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Pfizer Inc (2019-2024)
Table 40. Pfizer Inc Recent Developments
Table 41. Gilead Sciences Basic Information List
Table 42. Gilead Sciences Description and Business Overview
Table 43. Gilead Sciences Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 44. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Gilead Sciences (2019-2024)
Table 45. Gilead Sciences Recent Developments
Table 46. Genfit SA Basic Information List
Table 47. Genfit SA Description and Business Overview
Table 48. Genfit SA Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 49. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Genfit SA (2019-2024)
Table 50. Genfit SA Recent Developments
Table 51. Novartis AG Basic Information List
Table 52. Novartis AG Description and Business Overview
Table 53. Novartis AG Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 54. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Novartis AG (2019-2024)
Table 55. Novartis AG Recent Developments
Table 56. Intercepts Pharmaceuticals Basic Information List
Table 57. Intercepts Pharmaceuticals Description and Business Overview
Table 58. Intercepts Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 59. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Intercepts Pharmaceuticals (2019-2024)
Table 60. Intercepts Pharmaceuticals Recent Developments
Table 61. Cadila Healthcare Basic Information List
Table 62. Cadila Healthcare Description and Business Overview
Table 63. Cadila Healthcare Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 64. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Cadila Healthcare (2019-2024)
Table 65. Cadila Healthcare Recent Developments
Table 66. Novo Nordisk Basic Information List
Table 67. Novo Nordisk Description and Business Overview
Table 68. Novo Nordisk Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 69. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Novo Nordisk (2019-2024)
Table 70. Novo Nordisk Recent Developments
Table 71. Raptor Pharmaceutical Corp Basic Information List
Table 72. Raptor Pharmaceutical Corp Description and Business Overview
Table 73. Raptor Pharmaceutical Corp Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 74. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Raptor Pharmaceutical Corp (2019-2024)
Table 75. Raptor Pharmaceutical Corp Recent Developments
Table 76. Galmed Pharmaceuticals Basic Information List
Table 77. Galmed Pharmaceuticals Description and Business Overview
Table 78. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 79. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Galmed Pharmaceuticals (2019-2024)
Table 80. Galmed Pharmaceuticals Recent Developments
Table 81. Madrigal Pharmaceuticals Basic Information List
Table 82. Madrigal Pharmaceuticals Description and Business Overview
Table 83. Madrigal Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 84. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Madrigal Pharmaceuticals (2019-2024)
Table 85. Madrigal Pharmaceuticals Recent Developments
Table 86. Viking Therapeutics Basic Information List
Table 87. Viking Therapeutics Description and Business Overview
Table 88. Viking Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 89. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Viking Therapeutics (2019-2024)
Table 90. Viking Therapeutics Recent Developments
Table 91. Conatus Pharmaceuticals Basic Information List
Table 92. Conatus Pharmaceuticals Description and Business Overview
Table 93. Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 94. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Conatus Pharmaceuticals (2019-2024)
Table 95. Conatus Pharmaceuticals Recent Developments
Table 96. NGM Biopharmaceuticals Basic Information List
Table 97. NGM Biopharmaceuticals Description and Business Overview
Table 98. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 99. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of NGM Biopharmaceuticals (2019-2024)
Table 100. NGM Biopharmaceuticals Recent Developments
Table 101. CymaBay Therapeutics Basic Information List
Table 102. CymaBay Therapeutics Description and Business Overview
Table 103. CymaBay Therapeutics Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 104. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of CymaBay Therapeutics (2019-2024)
Table 105. CymaBay Therapeutics Recent Developments
Table 106. Boehringer Ingelheim Basic Information List
Table 107. Boehringer Ingelheim Description and Business Overview
Table 108. Boehringer Ingelheim Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 109. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Boehringer Ingelheim (2019-2024)
Table 110. Boehringer Ingelheim Recent Developments
Table 111. Eli Lilly and Company Basic Information List
Table 112. Eli Lilly and Company Description and Business Overview
Table 113. Eli Lilly and Company Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 114. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Eli Lilly and Company (2019-2024)
Table 115. Eli Lilly and Company Recent Developments
Table 116. Bristol Myers Squibb Basic Information List
Table 117. Bristol Myers Squibb Description and Business Overview
Table 118. Bristol Myers Squibb Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Products, Services and Solutions
Table 119. Revenue (US$ Million) in Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Business of Bristol Myers Squibb (2019-2024)
Table 120. Bristol Myers Squibb Recent Developments
Table 121. Key Raw Materials Lists
Table 122. Raw Materials Key Suppliers Lists
Table 123. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Downstream Customers
Table 124. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Distributors List
Table 125. Research Programs/Design for This Report
Table 126. Key Data Information from Secondary Sources
Table 127. Key Data Information from Primary Sources
Table 128. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Product Picture
Figure 2. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 4. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Report Years Considered
Figure 5. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Revenue in 2023
Figure 7. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Imaging Techniques Picture
Figure 9. Diagnostic Tests Picture
Figure 10. Biopsy Picture
Figure 11. Others Picture
Figure 12. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 13. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value Market Share by Type, 2023 & 2030
Figure 14. Product Picture of Hospital Pharmacy
Figure 15. Product Picture of Online Channels
Figure 16. Product Picture of Retail Channels
Figure 17. Product Picture of Others
Figure 18. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value Market Share by Application, 2023 & 2030
Figure 20. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
Figure 22. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
Figure 24. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia Pacific Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
Figure 26. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 27. South America Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Country (%), 2023 VS 2030
Figure 30. Key Countries/Regions Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value (%), (2019-2030)
Figure 31. United States Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)
Figure 32. United States Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
Figure 33. United States Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030
Figure 34. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)
Figure 35. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
Figure 36. Europe Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030
Figure 37. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)
Figure 38. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
Figure 39. China Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030
Figure 40. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)
Figure 41. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
Figure 42. Japan Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030
Figure 43. South Korea Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)
Figure 44. South Korea Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
Figure 45. South Korea Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030
Figure 46. Southeast Asia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)
Figure 47. Southeast Asia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
Figure 48. Southeast Asia Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030
Figure 49. India Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value, (2019-2030) & (US$ Million)
Figure 50. India Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Type (%), 2023 VS 2030
Figure 51. India Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Sales Value by Application (%), 2023 VS 2030
Figure 52. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Industrial Chain
Figure 53. Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Manufacturing Cost Structure
Figure 54. Channels of Distribution (Direct Sales, and Distribution)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
